Evidence map›Paper›PMID 32273477›Full record

ArticleHaematologica2021

Lifu Wang, Guilin Tang, L Jeffrey Medeiros, Jie Xu, Wenting Huang, Cameron C Yin, Michael Wang, Preetesh Jain, Pei Lin, Shaoying Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Should We Test forIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  13. The pathologic diagnosis of mantle cell lymphoma.Histology and histopathology · 2021
    Review
  14. Review
  15. Article
  16. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.Current hematologic malignancy reports · 2021
    Review
  17. Review
  18. Review
  19. ConcurrentCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lifu WangMD Anderson Cancer Center, Houston, USA and Henan Provincial People Hospital, China.
Guilin TangDept of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
L Jeffrey MedeirosDept of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Jie XuDept of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Wenting HuangMD Anderson Cancer Center, Houston, USA and National Cancer Center, Beijing, China.
Cameron C YinDept of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Michael WangDept. of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
Preetesh JainDept. of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
Pei LinDept. of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Shaoying LiDept. of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This study includes 88 MCL patients with MYC tested by fluorescence in situ hybridization and/or conventional cytogenetics, including 27 with MYC-R, 21 with MYC-EC, and 40 with normal (NL) MYC. MCL patients with MYC-R more often had blastoid/pleomorphic morphology; a higher frequency of CD10, MYC, and simultaneous MYC and BCL2 expression; a higher level of MYC; and a higher Ki67 proliferation rate (p<0.05) than those without MYC-R. Although patients with MYC-R more frequently received aggressive chemotherapy (p=0.001), their overall survival (OS) was significantly shorter than those without MYC-R. Compared with patients with MYC/BCL2 double hit lymphoma (DHL), patients with MYC-R MCL had a similar OS but more commonly had bone marrow involvement, stage 4 disease, and a different immunophenotype. MCL patients with MYC-EC showed an OS intermediate between those with MYC-R and MYC-NL, either all or only blastoid/pleomorphic MCL patients included. Multivariate analysis showed that MYC-R, but not MYC-EC, had an independent and negative impact on OS. In conclusion, MYC-R but not MYC-EC showed a higher MYC expression and is an adverse prognostic factor for MCL patients. Although the OS of MCL patients with MYC-R is similar to that of MYC/BCL2 DHL patients, these groups have different clinicopathologic features supporting the retention of MCL with MYC-R in the category of MCL, as recommended in the revised World Health Organization classification.

Indexed as

Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellAdultGene RearrangementHumansIn Situ Hybridization, FluorescencePrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-myc

Identifiers

PMID32273477
PMCPMC8094099
OpenAlexW3015920034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.